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Heart transplantation is an option for children with complex congenital heart disease and cardiomyopathies. A
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& INTRODUCTION
Heart transplantation is a therapeutic option for complex
congenital heart disease and treatment-refractory cardio-
myopathies. Some of the factors that affect the success of
this procedure were reviewed, including the indication
criteria for recipients and donors, immediate postoperative
management, immunosuppression, complications and sur-
vival.
The main indications for heart transplantation are as
follows: severe ventricular dysfunction despite optimized
drug therapy in patients with cardiomyopathies or who
have undergone corrective surgery for congenital heart
disease; treatment-refractory malignant arrhythmias; com-
plex congenital heart disease not surgically repaired;
unresectable cardiac tumors causing ventricular outlet
obstruction; unacceptable quality of life; heart failure stages
C and D; oxygen consumption less than 50% predicted for
age; and progressive pulmonary hypertension that prevents
heart transplantation (1-3).
The principal indications for transplantation in congenital
heart disease are as follows: hypoplastic left heart syndrome
with right ventricular dysfunction; pulmonary atresia with
significant obstructive anomalies of the coronary arteries;
interrupted aortic arch with severe subaortic obstruction;
severe unbalanced atrioventricular septal defect; various
single ventricle defects with subaortic obstruction; and
severe Ebstein’s anomaly. Dilated cardiomyopathies occur
most frequently, followed by restrictive cardiomyopathies
(1-6).
The contraindications for heart transplantation are the
following: uncontrolled systemic infection and sepsis;
irreversible pulmonary hypertension despite pulmonary
vascular reactivity tests; multiple organ failure; complex
genetic syndromes; severe central nervous system abnorm-
alities; psychiatric disorders; prematurity; uncontrolled
malignancy; and progressive systemic disease with early
mortality (genetic, metabolic and mitochondrial syndromes)
(1-4).
The preoperative evaluation includes the determination
of the pulmonary vascular resistance index. Children with
pulmonary vascular resistance indices greater than 6 Wood
units/m2 are more susceptible to the development of right
ventricular dysfunction and mortality. Currently, inhaled
nitric oxide and sildenafil citrate are administered post-
operatively to reduce the risk of pulmonary hypertension
crises (7-10).
The donor’s weight is another important consideration.
It is recommended that the donor weigh up to three times as
much as the recipient (11). If the donor weighs more than
the recipient, the latter may develop a syndrome character-
ized by hypertension, elevated intracranial pressure and
altered consciousness due to the higher stroke volume of the
donor’s heart (11).
Ischemic time must be carefully monitored; ischemic
times greater than three to four hours are associated with
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high mortality in the first 30 days because of primary graft
failure (11-13).
The panel reactive antibody (PRA) test indicates the
percentage of the recipient’s antibodies that react with
human leukocyte antigen (HLA), and patients with elevated
PRA scores are termed ‘‘sensitized’’. Therefore, it is crucial to
review the medical histories of both the donor and the
recipient, including blood product transfusions and previous
procedures (14-15). After the transplantation team has been
notified of a potential donor, a virtual crossmatch between
the recipient and donor is performed, and the transplantation
procedure begins, according to the results of crossmatch.
During the immediate postoperative period, the main
complications are primary graft failure, right ventricular
failure, pulmonary hypertension crisis, rejection and
infection.
The primary objective in the immediate postoperative
period is maintaining adequate cardiac output because
of denervation and ischemic time. The dependence on
vasoactive drugs occurs mainly in the first days post-
transplantation; it is recommended that these drugs be
administered by continuous infusion during the first 72
hours after surgery (11). The vasoactive drugs of choice
are dobutamine, milrinone, Isuprel and epinephrine (11).
The following parameters should be monitored during the
administration of vasoactive drugs: temperature, heart rate,
respiratory rate, blood pressure, central venous pressure,
left atrial pressure, mean pulmonary artery pressure, urine
output and venous oxygen saturation.
Primary graft failure is a major cause of immediate
mortality (prior to 30 days) after heart transplantation (15).
The treatment consists in some cases the use of mechanical
circulatory support or retransplantation. Prolonged ischemic
time is a primary risk factor for primary graft failure (2).
Pulmonary hypertension can be assessed by measuring
the pulmonary artery pressure and the right atrial pressure.
Right ventricular dysfunction and tricuspid regurgitation
secondary to pulmonary hypertension can be monitored
with echocardiography. Drugs such as non-selective sys-
temic vasodilators (sodium nitroprusside) and inhaled
nitric oxide (in selected cases) are used in combination
with inotropic drugs, such as dobutamine and milrinone.
Milrinone reduces pulmonary and systemic vascular resis-
tance and provides non-adrenergic inotropic support. In
cases of severe right ventricular failure, extracorporeal
membrane oxygenation may be indicated, but it increases
the risk of bleeding and neurological complications (15-20).
Patients with chronic congestive heart failure may exhibit
elevated systemic vascular resistance, which can lead to
paradoxical hypertension in the postoperative period.
Sodium nitroprusside and angiotensin inhibitors are drugs
used to manage systemic hypertension (15).
Hypertension caused by cyclosporine may develop in the
first weeks to months after transplantation, independent
of nephrotoxicity. This complication may even occur years
later and cause worsening renal function. The mechanisms
of cyclosporine-induced hypertension remain unclear. Some
studies have reported hypertensive patients with no renal
function changes (11,15).
Prophylactic therapy is used to prevent bacterial, cyto-
megaloviral (CMV), toxoplasmosis and fungal infections
(21-22). The choice of immunosuppressive regimens varies
among transplant centers. Immunosuppression protocols
for children may or may not include corticosteroids. A
triple (calcineurin inhibitor, cytostatic agent and steroids)
or double regimen (calcineurin inhibitor and cytostatic
agent) may be employed, with or without induction therapy
with antithymocyte globulin.
The most common calcineurin inhibitors are cyclospo-
rine and tacrolimus. Cyclosporine is initiated preoperatively
and discontinued during the cardiopulmonary bypass;
after surgery, it is then readministered intravenously at
a continuous dose of 0.1 mg/kg/h until the endotracheal
tube is removed from the patient. Following tube removal,
pediatric patients are administered oral cyclosporine at
an initial dose of 5 mg/kg/day, which is adjusted according
to the serum cyclosporine level, which is normally between
250 and 300 ng/ml. In patients with cyclosporine toxicity,
tacrolimus is administered at oral dose of 0.15 to 0.3 mg/
kg/day (14). Branco et al. (23) reported good outcomes after
converting from cyclosporine to tacrolimus in cases of
toxicity and refractory rejection of cyclosporine.
A cytostatic drug, such as azathioprine, is administered
at a oral dose of 1 to 3 mg/kg/day. The total number of
leukocytes is then monitored; a value greater than 4000
cells/mm3 is required. Mycophenolate may be administered
instead of azathioprine. Mycophenolate acts by inhibiting
the proliferation of lymphocytes; it can lead to bone marrow
suppression. The main side effect is gastrointestinal symp-
toms.
In addition to cytostatic agents and calcineurin inhibi-
tors, thymoglobulin and methylprednisolone are commonly
administered. The methylprednisolone dosage is based on
the child’s weight.
The main complications that can occur post-transplanta-
tion are described below.
& REJECTION
Acute rejection is the most common complication of
transplantation. Its incidence is high during the first four
months post-transplantation. Endomyocardial biopsy is
a diagnostic method that shows the degree and type of
rejection (24). However, acute rejection in children is
commonly diagnosed using noninvasive methods (2,25);
such as clinical symptoms, conventional electrocardiogram,
Doppler and tissue echocardiography, gallium-67 scintigra-
phy and BNP levels. The clinical signs of acute rejection
include cardiac arrhythmias and symptoms of congestive
heart failure, along with nonspecific signs, such as irrit-
ability and anorexia (14). An electrocardiogram showing a
decrease in the sum of the QRS voltages greater than 20%
may indicate acute rejection. Echocardiography may also
show ventricular dysfunction, increased cavity diameter,
septum and posterior wall thickness, atrioventricular valve
insufficiency, pericardial effusion and changes in ventricu-
lar diastolic function.
The treatment for acute rejection consists of maintaining
the rejection immunosuppression regimen (14). In patients
with stable hemodynamic parameters, methylprednisolone
is administered for four days. In cases in which the child
needs vasoactive drugs and ventricular dysfunction is
demonstrated by echocardiography, antithymocyte globulin
preparation is administered in addition to methylpredniso-
lone. Antithymocyte globulin is used for seven to ten days,
and it is monitored by measuring the level of T lymphocytes
in the peripheral blood; the requirement is fewer than
150 cells/mm3 by flow cytometry.
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Irradiation of lymphocytes (ILT) and methotrexate are
used as rescue therapeutic options in patients with refra-
ctory rejection.
Humoral rejection is diagnosed by microscopic and
immunofluorescence analyses of endomyocardial biopsy
specimens (24). Immunofluorescence findings may also
indicate immunoglobulin and complement deposition in
the vascular endothelium and evidence of endothelial cell
swelling. Humoral rejection is associated with sensitized
patients, high mortality, graft vascular disease development
and poor survival (12,15,24). Treatments for humoral
rejection include methylprednisolone, cyclophosphamide,
immunoglobulin, rituximab and plasmapheresis (12,15).
Hyperacute rejection is a form of humoral rejection that
occurs immediately after transplantation and is mediated
by preformed antibodies (15). These antibodies result from
previous exposure to human antigens (e.g., during preg-
nancy or blood transfusions), and they act directly against
antigens in the transplanted heart. Patients with hyperacute
rejection have poor prognoses and usually require assisted
circulation because of severe ventricular dysfunction.
& INFECTION
The infectious process represents a major cause of death in
the first year after transplantation. Schowengerdt et al. (21)
reported that among 332 patients undergoing heart transplan-
tation, there were 276 episodes of infection: 164 (60%) bacterial,
51 (18%) CMV, 19 (7%) fungal and 7 (2%) protozoal. Bacterial
infections occur more commonly in children under six months
of age at transplant, comprising 73% of all infections in this age
group, compared with 49% in children older than six months.
The highest incidence of bacterial infection occurs during the
first month after transplantation. The most common infections
are bronchopneumonia and bacteremia. CMV is responsible
for 59% of all viral infections, with the highest risk in the
first two months after transplantation. Factors associated with
CMV infection include age, mechanical ventilation, CMV
serologic status disparity (a positive donor and a negative
recipient) and prolonged ischemic time.
& HYPERTENSION
Hypertension is a frequent complication, occurring in
approximately 60% of patients within five years after
transplantation (4).
& GRAFT VASCULAR DISEASE
Graft vascular disease, one of the main factors limiting
long-term survival, may be related to both immunological
and non-immunological factors. Dobutamine stress echo-
cardiography has been used as a noninvasive diagnosis
method; however, coronary angiography and intravascular
ultrasonography are currently the methods of choice. The
potential risk factors for graft vascular disease are older age
and an increased number of rejections (25-29).
& TUMOR
The occurrence of tumors after heart transplantation is
termed post-transplant lymphoproliferative disease. These
tumors are predominantly of a B cell lineage and are usually
triggered by Epstein-Barr virus. This disease may occur in
5% of patients within five years after transplantation (25,29).
& RENAL COMPLICATIONS
Nephrotoxicity can be caused by the chronic use of
calcineurin inhibitors. Patients may develop severe renal failure,
which is defined as the need for dialysis or transplant (15,28).
& DYSLIPIDEMIA
Dyslipidemia is a common complication after cardiac
transplantation. Studies have produced conflicting results
regarding the association between dyslipidemia and immu-
nosuppressive drugs in children (15,23).
& SURVIVAL
As reported in the twelfth official pediatric registry of the
International Society for Heart and Lung Transplantation
(ISHLT) (28), the median patient survival depends on the
patient’s age at the transplant. In our setting, 133 patients
(4 were young adults) underwent transplantation, and five
underwent re-transplantation. Eighty-five patients were
alive from October 30, 1992 to November 3, 2013.
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